clinical trial · NCT05485766
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University·phase2·recruiting·n = 23
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast NeoplasmsBreast CancerBRCA1 MutationBRCA2 MutationBRCA MutationBRCA-Associated Breast CarcinomaPembrolizumabPaclitaxelCarboplatinOlaparibDefinitive Surgery
brief summary
This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline BRCA (gBRCA) 1/2 mutated triple negative breast cancer (TNBC). Pembrolizumab in combination with weekly paclitaxel and carboplatin (treatment 1) is followed by Pembrolizumab in combination with Olaparib (treatment 2) in neoadjuvant setting and Pembrolizumab in combination with Olaparib in adjuvant setting will be studied
started
Jul 16, 2024
primary completion
Jun 30, 2028
completion
Sep 30, 2028
last updated
Mar 20, 2025
official title
Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol